SCHEMBL21521769

SCHEMBL21521769

COC(=O)c1cccc(OCC[C@H]2C[C@@H](O[Si](C)(C)C(C)(C)C)CN2C(=O)O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
CYSLTR1 Q9Y271 1/20 0.39
KDM4E B2RXH2 2/20 0.38
NR1H4 Q96RI1 1/20 0.38
PPARG P37231 3/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
VDR P11473 2/20 0.37
MRGPRX4 Q96LA9 1/20 0.37
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21521010 0.91 CYSLTR1 (0.40) CYSLTR1KDM4ENR1H4PPARGVDR
SCHEMBL30101401 0.91 HCRTR1 (0.38) HCRTR1HCRTR2CYSLTR1KDM4ENR1H4
SCHEMBL30101468 0.81 CYSLTR1 (0.38) CYSLTR1KDM4ENR1H4PPARGVDR
SCHEMBL21521768 0.80 NR1H4 (0.37) CYSLTR1KDM4ENR1H4PPARGALDH1A1
SCHEMBL4299042 0.77 ABHD6 (0.36) RAB9ANPC1MAPK1
SCHEMBL4297705 0.76 NPC1 (0.40) KDM4EALDH1A1RAB9ANPC1LMNA
SCHEMBL4286140 0.75 HCRTR1 (0.44) HCRTR1HCRTR2CYSLTR1KDM4EPPARG
SCHEMBL10145035 0.73 MAPT (0.49) CYSLTR1KDM4ENR1H4PPARGALDH1A1
SCHEMBL28522052 0.72 BTN3A1 (0.33) ALDH1A1HSD17B10THRB
SCHEMBL2808314 0.72 ALDH1A1 (0.48) CYSLTR1KDM4EALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4234551-A2 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2023-08-30 EP disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 US disclosed
EP-3788040-B1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS INC (US) 2023-04-12 EP disclosed
US-11566020-B1 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2023-01-31 US disclosed
US-11014913-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2021-05-25 US disclosed
EP-3788040-A1 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2021-03-10 EP disclosed
CN-112424188-A Pyridazinones as PARP7 inhibitors 里邦医疗公司 2021-02-26 CN disclosed
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2021-01-28 US disclosed
US-10870641-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2020-12-22 US disclosed
US-20200123134-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2020-04-23 US disclosed
US-10550105-B2 Pyridazinones as PARP7 inhibitors Ribon Therapeutics Inc. (US) 2020-02-04 US disclosed
US-20190330194-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2019-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 HCRTR1 4792/4885HCRTR2 4717/4885CYSLTR1 4202/4885
US-10550105-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 HCRTR1 4792/4885HCRTR2 4717/4885CYSLTR1 4202/4885
US-20190330194-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 HCRTR1 4792/4885HCRTR2 4717/4885CYSLTR1 4202/4885
US-11014913-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 HCRTR1 4792/4885HCRTR2 4717/4885CYSLTR1 4202/4885
US-11566020-B1 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 HCRTR1 4792/4885HCRTR2 4717/4885CYSLTR1 4202/4885
US-10870641-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 HCRTR1 4792/4885HCRTR2 4717/4885CYSLTR1 4202/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 HCRTR1 4792/4885HCRTR2 4717/4885CYSLTR1 4202/4885
US-20200123134-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 HCRTR1 4792/4885HCRTR2 4717/4885CYSLTR1 4202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.